Boston Scientific BSX posted another quarter of robust results. As the firm is on track to meet our full-year expectations, we’re leaving our $55 fair value estimate unchanged. Boston saw quarterly ...
Pidlite expects to deliver double-digit volume growth in H2 with higher EBITDA “We see momentum to continue. Therefore, the underlying double-digit volume growth that we delivered in the first half, ...
Pidilite Industries expects a 'double digit underlying volume growth' in the second half of the current fiscal, helped by its growth brand steps, along with product innovation and marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback